CClinicalTrials.gg
Sign In
RecruitingNCT07361471ORTRAIUpdated Feb 20, 2026

Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

An interventional study of molecular analysis in Ovarian Cancer, sponsored by Centre Jean Perrin. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Centre Jean Perrin · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.

The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.

The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

02

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • ovarian cancer
  • long responder
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.

  • Corresponding to one of the two groups below:

    • Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
    • Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
  • Affiliation to a social security scheme
  • Patient who signed the genetic consent form

Exclusion criteria

Exclusion Criteria:

  • Minor patient
  • Pregnant patient
  • Patient under guardianship or conservatorship
  • Patients who object to the collection of their medical/paramedical data
  • Patient for whom the center does not have biological material for genomic analysis (FFPE block)
  • Patient under administrative, judicial decision or AME (State Medical Aid)
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    long-term responders

    molecular analysis on histological blocks

    Genetic: molecular analysis

Interventions

  • Geneticmolecular analysis

    molecular analysis on histological blocks

05

What researchers measure

Primary outcomes

  1. Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.

    Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Phenotypic criteria differences between refactory patients and long responder patients

    Phenotypic criteria will include BMI, personal history and family history

    Time frame: Through study completion, an average of 1 year

  2. Clinical criteria differences between refactory patients and long responder patients

    Clinical criteria will include age at diagnosis, FIGO stage, initial PCI score, CCO score

    Time frame: Through study completion, an average of 1 year

  3. Biological criteria difference between refactory patients and long responder patients

    Biological criteria include CA-125

    Time frame: Through study completion, an average of 1 year

  4. Histological criteria differences between refactory patient and long responder patients

    Histological criteria include histological type, presence of emboli, Ki-67, RO, RP, WT1, PAX8, PD-L1, CD8, p53, HER2

    Time frame: Through study completion, an average of 1 year

06

Study locations

1 of 1 sites recruiting
  • Centre Jean Perrin
    Clermont-Ferrand, PUY DE DOME 63001, France
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07361471
Lead sponsor
Centre Jean Perrin
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Jan 22, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Judith PASSILDAS JAHANMOHAN, PhD
Contact
judith.passildas@clermont.unicancer.fr
0463663337 ext. +33
Tressie HERRMANN, MD
principal investigator · Centre Jean Perrin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ovarian Neoplasms→

Other studies from this sponsor

Centre Jean Perrin

Start the discussion